Select Your Region
Global
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib
- Cancer
- Lung Cancer
- Non-Small Cell Lung Cancer (NSCLC)
- Non Small Cell Lung Carcinoma
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:
Active, not recruiting
This study runs in
Cities
- Abu Dhabi
- Adana
- Ankara
- Antalya
- Auderghem
- Barnaul
- Bedford Park
- Beograd
- Bogotá
- Brescia
- Brno
- București
- Burgas
- Cagliari
- Cali
- Camperdown
- Changsha
- Chelyabinsk
- Ciudad Autonoma Buenos Aires
- Cluj-Napoca
- Cremona
- Denizli
- Dubai
- East Melbourne
- Edirne
- Genova
- Gent
- Guangzhou
- Haifa
- Hangzhou City
- Hanoi
- Hasselt
- Iasi
- Istanbul
- Izmir
- Jinan
- Kaunas
- klagenfurt-am-worthersee
- Kortrijk
- Krasnoyarsk
- La Habana
- Lima
- Liverpool
- Liège
- Malatya
- Medellín
- Meldola
- Montevideo
- Nanjing
- Nanning
- Nis
- Novara
- Olomouc
- Osijek
- Padova
- Palermo
- Panagyurishte
- Perugia
- pesochny
- Petach Tikva
- Plovdiv
- Porto
- Praha 4 - Krc
- Ramat Gan
- Reggio Calabria
- Roma
- Ronse
- Santiago
- Sint-Niklaas
- Sofia
- Sremska Kamenica
- St Leonards
- Taiyuan
- Tampere
- Taranto
- Tel Aviv
- Tianjin
- Timisoara
- Torrette
- Turku
- UFA
- Vila Nova de Gaia
- Wien
- Wuhan
- Xuzhou
- Zagreb
Trial Identifier:
NCT04764188 MO42122
Study Summary
This study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with alectinib in real-world clinical practice.
Hoffmann-La Roche
Sponsor
N/A
Phase
NCT04764188, MO42122
Trial Identifier
Alectinib
Treatments
NSCLC
Condition
Official Title
A Multicenter Non-Interventional Cohort Study to Evaluate the Real-World Clinical Management and Outcomes of Patients Diagnosed With ALK-Positive Advanced NSCLC Treated With Alectinib (ReAlec)
Eligibility Criteria
All
Gender
≥18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Confirmed diagnosis of advanced NSCLC (stage IIIB, IIIC, IVA, or IVB) on or after the date of local approval for alectinib as first-line treatment and/or second-line treatment for ALK-positive advanced NSCLC and planned to receive treatment as per routine for at least one cycle (28 days) while on study
- ALK-positive as confirmed by immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), next generation sequencing (NGS), or other non-specified sequencing methods, documented prior to receiving treatment with an ALK inhibitor
- Cohort 1: Currently receiving, or planned to receive, treatment for ALK-positive advanced NSCLC with alectinib as first-line treatment
- Cohort 2: Planned to receive treatment for ALK-positive advanced NSCLC with alectinib as second-line treatment
- Able to be followed-up by participating site
- Participants with advanced NSCLC who have CNS metastases are eligible for inclusion
Exclusion Criteria
- Participants not receiving alectinib for the treatment of ALK-positive advanced NSCLC according to standard of care and in line with local product information
- Participants not receiving the Roche studied medicinal product
- Participants who have received or are currently receiving alectinib as an investigational study drug in a clinical trial for the treatment of advanced NSCLC
For the latest version of this information please go to www.forpatients.roche.com